Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

Abramson Cancer Center at Penn Medicine1 site in 1 country18 target enrollmentJanuary 19, 2018

ConditionsProstate Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Prostate Cancer
Sponsor: Abramson Cancer Center at Penn Medicine
Enrollment: 18
Locations: 1
Primary Endpoint: number of subjects who successfully complete Rb-82 myocardial PET Imaging assessments
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To determine the feasibility of using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen- deprivation therapy with external beam radiation therapy.

Registry

clinicaltrials.gov

Start Date

January 19, 2018

End Date

October 19, 2019

Last Updated

last year

Study Type

Observational

Sex

Male

Investigators

Sponsor

Abramson Cancer Center at Penn Medicine

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Either clinically localized prostate cancer or biochemically-recurrent prostate cancer patients who are planned for at least 6 months ADT with a GnRH agonist and curative-intent radiation therapy per their oncologic providers.
•Over 50 years of age. Calculated 10-year Framingham General Cardiovascular Risk Score of ≥10% at the time of planned initiation of ADT.
•Patients must be able to read and understand English.
•Participants must sign the informed consent form.

Exclusion Criteria

•Prior treatment with GnRH agonist therapy.
•History of active asthma or other reactive airway disease.
•Ischemic cardiac event (myocardial infarction, unstable angina) within the preceding 6 months.